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The intraventricular administration of [3H-methyl]-methionine resulted in a 
steady increase in carboxyl-[~H]methylated protein formation in the brain of 
developing rats (2-42 days). The analysis by gel filtration on Sepharose-4B 
of Lubrol-Px-SOlubilized membrane proteins, ~neluding benzodiaz~pine receptor 
proteins, revealed co-migration of carboxyl-[JH]methylated and [JH]flunitraze- 
pam-binding protein species. The latter displayed a single pe~k at 2 days and 
2-3 p~aks subsequently. At 26 days the lighter of the two [~H]flunitraz~pam 
and [ H]muscimol-binding peaks associated with the principal carboxyl-[~H] - 
methylated protein peak. The findings suggest the participation of carboxyl- 
methylation in the maturation of benzodiazepine receptor proteins. 
Although carboxylmethylation is a well recognized post-translational 
protein modification (1,2) involving exclusively aspartic and glutamic acid 
residues, little is known regarding its ontogeny in brain tissue. Paik et 
al. (3) reported a slow increase in activity of protein methylase II (PM II), 
(EC 2.1.1.24), the carboxylmethylating enzyme, during the first 10 days of 
life in rat brain, while, in the mouse, Clark et al. (4) reported a 2-3 fold 
increase in cerebral PM II after gestation day 19 and adult levels by 30 days 
post-natally. Similarly, Kloog et al. (5) noted that PM II activity of neuro- 
blastoma cells increases in parallel with their differentiation. 
In contrast to the meager knowledge about the ontogeny of cerebral 
protein carboxylmethylation, there is ample information regarding the ontogen- 
etic development of the cerebral benzodiazepine (Bz)-Y-aminobutyric-acid- 
(GABA)-chloride channel receptor complex (6,7). Ontogenetic studies (8-10) 
have revealed an early development of Bz-reoeptors, present at birth, and a 
differential rate of formation of the associated proteins in different brain 
regions (8-10). The pharmacologically distinct type I and type 2 Bz-receptors 
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(11) have also been shown to develop differentially, as has the ability of 
GABA to modulate the binding of [3H]flunitrazepam to the cerebral Bz-receptor 
(12). 
In view of these facts, a relevant question arose: is carboxylmethyla- 
tion implicated in the ontogeny of Bz-receptor proteins? Since another neural 
receptor complex, the nicotinic acetylcholine receptor (13), is an excellent 
methyl accepting protein in vitro, experiments designed to obtain an answer to 
the above question appeared desirable. In the present study we measured the 
carboxylmethylation in vivo of detergent-solubilized, Bz-receptor-containing 
rat brain membrane proteins (14) at 4 early post-natal time points and we 
determined, in parallel, their ability to bind [3H]flunitrazepam and, in one 
case, [3H]muscimol, as well. 
The results indicate that, while at 2 days, the peak of [3H]flunitrazepam 
binding associated with proteins of low carboxyl-[3H]methyl content, at 17, 26 
and 42 days, [3H]flunitrazepam binding associated with proteins of significant 
carboxyl-[3H]methyl content. In addition, our data show a single, soluble 
[3H]flunitrazepam-binding protein peak at 2 days and 2 to 3 such peaks at 17, 
26 and 42 days. 
MATERIALS AND METHODS 
Animals and Chemicals 
Male rats (Sprague-Dawley) were from Spartan (Haslett, MI). 
methionine (8-10 Ci/mmole) was from ICN Pharmaceuticals (Irvine, 
methyl]-flunitrazepam (78 Ci/mmole), [3H_methylamino]_muscimol 





was from Pharmacia (Piscataway, NJ). Nonradioactive flunitrazepam was a gift 
from Hoff~nan-La Roche, Inc. All reagent chemicals were from Sigma. The GF/B 
filters were from Whatman. Polyethylene glycol (8,000) was from Sigma. 
$olubilization Procedure 
Animals under light ether anesthesia were injected into the right lateral 
cerebral ventricle with 10-30 uCi of [JH-methyl]-methionine in 10-15 ul of 
artificial cerebrospinal fluid (Merlis solution). The rats were decapitated 
one hour later together with an equal number of naive littermates. The two 
sets of brains (minus cerebellum) were homogenized in 8-10 volumes of ice-cold 
10 mM sodium phosphate buffer, pH 6.8, containing 0.2M NaCI and the protease 
inhibitors listed by Stephenson and Olsen (15) using the Polytron homogenizer 
(2 x 5 sec bursts, 15 sec apart, setting 5 on the scale of 8). The homogen- 
ates were centrifuged at 100,000 x g for 60 min, the resulting pellets were 
resuspended in the above buffer containing I% Lubrol-P and were allowed to 
stand at OUC for 30 min. Subsequent centrifugation at I0~,000 x g for 60 min 
yielded Lubrol-solubilized proteins (fraction S L) as supernatants. 
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Gel Filtra$ion of Frac$ion SL 
Immediately after its preparation, the radioactive fraction SL(30-40 mg 
protein) was injected on a 2.5 x 50 cm column of Sepharose-4B, equilibrated 
with homogenization buffer containing 0.2% of Lubrol-P., but no bacitracin and 
• . X 
benzamidlne. 2.8 ml fraetlons were collect~d at a flow rate of 30 ml/h and 
I-2 ml aliquots were assayed for carboxyl-[ H]methyl containing proteins. The 
non-radioactive S, fraction was similarly fractionated and the binding of 
ligands to the el~ate was determined. All chromatographic operations were 
carried out at 4°C. 
AssaYs 
Protein carboxylmethylation was determined according to O'Dea et al. 
(16). Briefly, I-2 ml aliquots were precipitated with trichloracetic acid 
(TCA), the methyl groups were hydrolyzed in alkali and the formed methanol was 
extracted with toluene: isoamyl alcohol (3:2). The difference between total 
and nonvolatile radioactivity was used as index of protein carboxylmethyla- 
tion. Binding of [~H]-flunitrazepam was determined at 5 nM after 30 min 
o 
incubation at 0 C. The samples were precipitated with polyethylene glycol 
(8,000) and filtered through GF/B flters under reduced pressure (17). Washed 
a~d dried filters were counted in 7 ml ACS with 42-45% efficiency. 
[JH]muscimol binding was determined by the same method at 50 nM except the 
incubation time was 15 min. For non-specific binding cold flunitrazepam and 
GABA in 1000-fold excess were used. 
Protein concentrations were determined by a modified Lowry method (18) 
employing sodium dodecyl sulfate to avoid Lubrol-P interference. Bovine 
X 
serum albumin was used as standard. 
RESULTS AND DISCUSSION 
Following the intraventricular injection of [3H-methyl]-methionine, its 
uptake by brain cells and its conversion to [3H-methyl]-S-adenosyl-L- 
methionine (AdoMet) by cerebral S-adenosylmethionine synthase (EC 2.5.1.6), 
part of the [3H-methyl] group of AdoMet became transferred to the free 
carboxyl groups of selected aspartic and glutamic acid protein residues by PM 
II (I). Figure I clearly shows the steady increase in carboxylmethylation of 
homogenate proteins with age, while Table I shows that the proportion of the 
total homogenate radioactivity converted to protein carboxyl-[3H]methyl 
residues quadrupled between days 2 and 42. A similar increase is seen in the 
homogenate as well as in Fraction S L when the data is expressed as dpm/mg of 
protein per I uCi of radioactivity present in I g of brain wet weight (Table 
2). Our findings confirm, in the developing rat brain in vivo, the recent 
results of Clark et al. (4) who showed that protein carboxylmethylation, 
measured in mouse brain minces, keeps increasing up to about 30 days 
post-natally. In vitro measurements of cerebral PM II acting on gelatin 
yielded similar results (3). 
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In vivo carboxylmethylation of rat brain proteins during early post- 
natal development. 
Protein carboxylmethylation in homogenates was determined as described 
(16). Total homogenate radioactivity was determined on 20 ul aliquots 
of ten times diluted suspensions by direct counting in 10 ml of ACS. 
The number of rats was as follows: (age in days in parenthesis) 10 
(2), 9 (7), 6 (13), 4(16), 5 (20), 8 (26), 3 (29), 2 (31) and 3 (42). 
The points represent triplicate measurements for a single experiment 
for 2, 7, 13, 20, 29, 31 and 42-day old animals and averages of 4 and 
5 experiments for 16 and 26-day old a~imals. The ordinate refers to 
the radioactivity (DPM) as carboxyl-[JH]methyl groups divided by the 
total radioactivity in uCi present in the homogenate. 
The in v~vo carboxyl-[3H]methylated,- Lubrol-P -solubilized proteins 
x 
contained in Fraction S L (Table 3) could be resolved into distinct subpopula- 
tions upon gel filtration on Sepharose-4B. Since, however, the main objective 
of gel filtration was to compare the age profiles of the carboxyl-[3H]- 
methylated proteins to the corresponding profiles marking Bz-receptor 
activity, possible differential losses in carboxyl-[3H]methyl groups due to 
the relatively low acidity of the chromatographic buffer (pH 6.8) were not 
rigorously controlled and therefore the reported radioactivities represent 
minimum values. Although several workers (15,17,19-25) have analyzed solubil- 
ized Bz-receptor proteins from adult brains, no study has appeared, to our 
knowledge, in which such proteins were examined during early brain develop- 
Table I. The effect of age on the carboxylmethylation of brain proteins 
in v ~ v 9  
Age, Days Total Radioactivity Carboxyl- 3rH]Methylated Proteins 
dpm x 10 -6 dpm x 10 -4 % of total 
2 25.50 2.60 0.103 
17 18.90 2.70 0.143 
26 11.70 3.86 0.330 
42 4.64 1.95 0.420 
1 0 5 9  
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Table 2. The effect~of age on the specific radioactivity of 
carboxyl-[JH]methylated brain proteins. 
Age, days Homogenate Fraction S L 
(dpm/mg protein)* (dpm/mg protein)* 
2 44 60 
17 50 85 
26 77 88 
42 143 200 
* The specific activity values shown were normalized by dividing 
by the total radioactivity/gram wet weight (uCi/g) (see text). 
ment. Figure 2 (panel A) reveals a single, rather broad, peak of [3H]fluni- 
trazepam-binding activity and two distinct peaks of carboxyl-[3H]methylated 
protein at 2 days; two distinct [3H]flunitrazepam-binding peaks became 
apparent at 17 days, one of which (tubes 37-43) clearly associated with 2 
peaks of carboxyl-[3H]methylated 
second [3H]flunitrazepam-binding 
principal carboxyl-[3H]methylated 
protein. At 26 days (panel C), the smaller 
activity peak again associated with the 
proteins. [3H]muscimol-binding to the same 
eluate also had 2 peaks, the second of which clearly associated with the 
highest carboxyl-[3H]methylated protein peak. At 42 days (panel D) [3H]fluni- 
trazepam-binding activity and carboxyl-[3H]methylated proteins also shared a 
substantial portion of the eluate, namely, tubes 35-41. 
Table 3. Protein carboxylmethylation and TCA-insoluble ~adioactivity in a 
20-day old rat brain after a I hour pulse of [JH-methyl]-methionine.* 
Fraction 
TCA-Insoluble** Carboxyl-[3H] - 
Radioactivity Methylated Proteins 
dpm/mg protein 
Homogenate 41,300 172 
Fraction S 42,700 207 
Sepharose-~B peak*** 61,400 285 
* The injections were 12 uCi per animal. Five brains were pooled and the 
procedure outlined in Methods was followed. 
** Aliquots of fractions were precipitated with 10% TCA, washed twice with 5% 
TCA, the pellets were digested with NCS and counted after addition of 10 
ml ACS. 
*** F~actions from Sepharose 4B chromatography with high capacity for 
[JH]-flunitrazepam were pooled and assayed. 
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Fig. 2. Sepharose-4B chromatography of Lubrol P -solubilized rat brain 
• X 
membrane protelns. Fraction SL, prepared from brains of 2, 17, 26-and 
42 day old rats, half of which were injected intraventricularly with 
[JH-methyl] methionine (see Methods), were successively passed 
(radioactive fraction first) through a column of Sepharos~-4B, as 
described in Methods.~ The ordinates (Q .... o), carboxy~-[ H]methylated 
proteins, (o .... o), [JH]-flunitrazepam and (o- - o), [JH]muscimol 
binding are expressed as % of maximum. 
The presence of more than one peak of soluble --[3H]flunitrazepam-binding 
activity in the brain of 17, 26 and 42-day old rats and of a single peak in 
the brain of 2-day old rats, represents a novel finding. Sieghart and Mayer 
(26) analyzed the post-natal development of Bz-receptors by SDS gel electro- 
phoresis after photoaffinity labelling with [3H]-flunitrazepam. Up to 8 days 
of age, [3H]-flunitrazepam labelled predominantly the P55 and P59 polypeptides 
while, in the second post-natal week the labelling shifted to a lighter, P51 
polypeptide. Our results are consistent with the notion that, as the Bz- 
receptor proteins mature, their multiplicity temporarily increases until, in 
the adult brain, the Bz-receptor complex reaches a definitive size and, hence, 
exhibits a single molecular weight in soluble form (15,17,19-21,23). 
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The evidence of an apparent co-migration of the in vivo carboxyl-[3H]- 
methylated proteins with [3H]flunitrazepam-binding proteins at 17, 26 and 42 
days but not at 2 days (Figure 2) suggests, without as yet proving, that 
carboxylmethylation plays a role in the maturation of the Bz-receptor 
proteins. Given that both PM II activity and Bz-receptor binding are present 
prenatally and increase dramatically in the first 3 post-natal weeks (4.,10) it 
is attractive to speculate that carboxylmethylation participates in the 
terminal phase of the receptor's maturation process. At that time, the 
Bz-receptor complex speciates into pharmacologically diverse subclasses (11) 
and, in general, acquires both the molecular and physiological characteristics 
of adulthood (27). 
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